Tower Research Capital (TRC)’s Kronos Bio KRON Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-6,079
| Closed | -$5.01K | – | 5440 |
|
|
2025
Q1 | $5.01K | Buy |
6,079
+3,878
| +176% | +$3.73K | ﹤0.01% | 4173 |
|
|
2024
Q4 | $2.09K | Sell |
2,201
-1,922
| -47% | -$1.81K | ﹤0.01% | 4907 |
|
|
2024
Q3 | $4.12K | Sell |
4,123
-1,417
| -26% | -$1.57K | ﹤0.01% | 4664 |
|
|
2024
Q2 | $6.87K | Sell |
5,540
-9,649
| -64% | -$9.83K | ﹤0.01% | 4529 |
|
|
2024
Q1 | $19.7K | Buy |
15,189
+15,117
| +20,996% | +$17.2K | ﹤0.01% | 3012 |
|
|
2023
Q4 | $90 | Buy |
+72
| New | +$80 | ﹤0.01% | 5724 |
|
|
2023
Q2 | – | Sell |
-7,062
| Closed | -$10K | – | 6224 |
|
|
2023
Q1 | $10K | Sell |
7,062
-12,882
| -65% | -$24.7K | ﹤0.01% | 4364 |
|
|
2022
Q4 | $32K | Buy |
19,944
+2,980
| +18% | +$6.86K | ﹤0.01% | 2690 |
|
|
2022
Q3 | $57K | Buy |
16,964
+13,656
| +413% | +$61.6K | ﹤0.01% | 3041 |
|
|
2022
Q2 | $12K | Buy |
3,308
+719
| +28% | +$3.26K | ﹤0.01% | 4285 |
|
|
2022
Q1 | $19K | Sell |
2,589
-1,396
| -35% | -$11.9K | ﹤0.01% | 3582 |
|
|
2021
Q4 | $54K | Buy |
3,985
+3,017
| +312% | +$47.2K | ﹤0.01% | 2710 |
|
|
2021
Q3 | $21K | Sell |
968
-504
| -34% | -$10.8K | ﹤0.01% | 3666 |
|
|
2021
Q2 | $35K | Buy |
1,472
+686
| +87% | +$17.4K | ﹤0.01% | 3325 |
|
|
2021
Q1 | $23K | Sell |
786
-19
| -2% | -$557 | ﹤0.01% | 3778 |
|
|
2020
Q4 | $24K | Buy |
+805
| New | +$25.3K | ﹤0.01% | 3745 |
|
Tower Research Capital (TRC)'s KRON Position: Q2 2025 in Review
Tower Research Capital (TRC) sold out of Kronos Bio (KRON) in Q2 2025, closing a stake of 6,079 shares — an estimated $5.01K sold.
Tower Research Capital (TRC) first reported a position in KRON in Q4 2020 and held it in 16 quarters. The position peaked at $57K in Q3 2022. 0 funds tracked by Wall St. Rank hold KRON as of Q2 2025.
- Tower Research Capital (TRC) reported no remaining Kronos Bio position as of Q2 2025 after selling out during the quarter.
- Tower Research Capital (TRC) sold 6,079 Kronos Bio shares in Q2 2025, an estimated $5.01K.
- Tower Research Capital (TRC) first reported a position in Kronos Bio in Q4 2020 and held it in 16 quarters.
- Tower Research Capital (TRC)'s Kronos Bio position peaked at $57K in Q3 2022.
- 0 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2025, filed 15 Aug 2025.